AlloVir, Inc. (ALVR) closed the last trading session at $7.83, gaining 45.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High?
AlloVir, Inc. (ALVR) closed the last trading session at $7.65, gaining 9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AlloVir, Inc. (ALVR) been one of those stocks this year? A ...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both ...
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the posoleucel Phase 3 Studies were ...
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired AlloVir, Inc. (NASDAQ: ALVR ...
As of February 8, 2023, the average one-year price target for Allovir is $26.78. The forecasts range from a low of $23.23 to a high of $31.50. The average price target represents an increase of 343.29 ...
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the posoleucel Phase 3 Studies were ...
B of A Securities analyst Jason Zemansky initiated coverage on AlloVir Inc ALVR with a Buy rating and announced a price target of $17. AlloVir is a clinical-stage biotech advancing cell therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results